预约演示
更新于：2025-06-20
Capecitabine
卡培他滨
更新于：2025-06-20
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1998-04-30), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C15H22FN3O6 |
InChIKeyGAGWJHPBXLXJQN-UORFTKCHSA-N |
CAS号154361-50-9 |
关联
2,192
项与 卡培他滨 相关的临床试验NCT05296005
Total Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction (GEJ) and Gastric Cancers: A Pilot Trial
NCT05375708
A Multicenter Phase II Randomized Trial to Evaluate Systemic Therapy Versus Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer
NCT06291064
TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)
100 项与 卡培他滨 相关的临床结果
登录后查看更多信息
100 项与 卡培他滨 相关的转化医学
登录后查看更多信息
100 项与 卡培他滨 相关的专利（医药）
登录后查看更多信息
13,534
项与 卡培他滨 相关的文献（医药）2025-12-01Journal of Gastrointestinal Cancer
Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT)
Article
作者: Naik, Nagendra ; Priyanka, Parul ; Agrawal, Sushma
INTRODUCTION:
Retroperitoneal lymphadenopathy is considered a metastatic disease in GBC; however, some surgical series of radical surgery with enlarged RPLN who underwent RPLN dissection have shown results marginally inferior to those without enlarged RPLN. Radiological RPLN comprises a major proportion of advanced non-metastatic GBC. There is dilemma in the intent of treatment to be offered in such cases. We are reporting our series of outcome of GBC with RPLN treated with first-line CT followed by consolidation CTRT.
MATERIALS AND METHODS:
Non-metastatic locally advanced GBC with good performance status (KPS ≥ 80) were initiated on first-line CT (cisplatin-gemcitabine), and thereafter, responders were evaluated by CECT-angiography and PET-CT scan for resectability. If found unresectable, they were offered consolidation CTRT to a dose of 45 Gy by conventional fractionation (3D-CRT technique) along with concurrent capecitabine at 1250 mg/m2 to GBC and regional lymphatics including RPLN. Thereafter, boost dose of 9 Gy/5# was given to GBC only. Response assessment was done using CECT abdomen by RECIST criteria v 1.1. Outcomes (overall survival) of the two groups (RPLN vs non-RPLN) were computed with Kaplan-Meier survival curves and chi-square tests using SPSS v 20.
RESULTS:
Among 189 patients of advanced non-metastatic GBC recruited from 2011 to 2022, 80 had RPLN. The demographic features of both groups were comparable. Overall, 68% of the patients were women, 30% underwent upfront stenting for obstructive jaundice, and 90% had T3 and T4 disease. Only 10% had undergone upfront laparoscopic staging and had pathologically proven RPLN. Forty percent of the patients received four cycles of CT only and 50% of the patients received six cycles or more and 33% received CTRT. By RECIST criteria, 10% vs 16% achieved complete response (CR), 39% vs 41% achieved partial response (PR), 16% vs 15% achieved stable disease (SD), 2.7% vs 6% had disease progression (PD), and 14.5% vs 3.7% were non-evaluable in non-RPLN group vs RPLN group, respectively. 12% vs 6% could undergo radical surgery in non-RPLN group vs RPLN group (p = 0.03). The median OS was 9 months (95% CI 7.6-10.3 months) vs 10 months (95% CI 8-9.8 months) (p = NS) in non-RPLN group vs RPLN group, respectively. In those who received CT only, the median OS was 7 months vs 8 months, while in those who received CT followed by CTRT, the median OS was 14 months vs 13 months (p = 0.65) in non-RPLN group vs RPLN group, respectively.
CONCLUSIONS:
Based on this analysis, we conclude that RPLN constitutes a major proportion of advanced non-metastatic GBC and has outcomes similar to those without RPLN if treated with radical intent. RPLN should not be considered a metastatic disease and should be treated with radical intent.
2025-12-01Journal of Gastrointestinal Cancer
Development of a Prognostic Nomogram for Overall Survival in Gastric Cancer Patients Who Underwent Adjuvant Chemoradiotherapy
Article
作者: Avci, Hanife ; Ozyurek, Yasin ; Hurmuz, Pervin ; Yilmaz, Melek Tugce ; Yigit, Ecem ; Dag, Osman ; Cengiz, Mustafa
PURPOSE:
The aim of this study was to identify prognostic factors influencing overall survival (OS) in patients with gastric cancer treated with adjuvant chemoradiotherapy (CRT) and to develop a predictive model.
METHODS:
We retrospectively evaluated 245 non-metastatic gastric cancer patients who received adjuvant CRT or radiotherapy from 2010 to 2020. Survival analyses were performed using the Kaplan-Meier method. Prognostic factors were identified through univariate and multivariate Cox regression analyses. A nomogram was constructed based on significant predictive factors for OS, including lymph node ratio, T classification, tumor location, and local recurrence.
RESULTS:
The median follow-up duration was 41.5 months (range, 6-144.8 months). The 2- and 5-year OS and progression-free survival were 77% and 53% and 64% and 49%, respectively. In multivariate analysis, tumor location (distal vs. proximal), pT classification (pT1-2 vs. pT3-4), lymph node ratio (< 0.18 vs. ≥ 0.18), and presence of local recurrence were independent prognostic factors for OS. The optimal cut-off value for the total nomogram score predicting OS was 116 points. Patients with < 116 points had 2- and 5-year OS rates of 87% and 73%, respectively, compared to 67% and 30% for those with ≥ 116 points.
CONCLUSION:
A nomogram was constructed incorporating lymph node ratio, T classification, tumor site, and local recurrence for gastric cancer patients receiving adjuvant CRT. Patients with a total score below 116 demonstrated higher survival rates. This nomogram may aid in defining optimal follow-up intervals.
2025-12-01CANCER CHEMOTHERAPY AND PHARMACOLOGY
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing
Article
作者: Villano, John L ; Pandey, Deepali ; Roberts, Danielle ; Williams, Abby ; Shamaei Zadeh, Alexia
PURPOSE:
Patients with partial or complete DPD deficiency have decreased capacity to degrade fluorouracil and are at risk of developing toxicity, which can be even life-threatening.
CASE:
A 43-year-old man with moderately differentiated rectal adenocarcinoma on capecitabine presented to the emergency department with complaints of nausea, vomiting, diarrhea, weakness, and lower abdominal pain for several days. Laboratory findings include grade 4 neutropenia (ANC 10) and thrombocytopenia (platelets 36,000). Capecitabine is used as a component of first-line adjuvant therapy by approximately 2 million patients worldwide each year. Capecitabine is metabolized to fluorouracil via the enzyme dihydropyrimidine dehydrogenase (DPD). With worsening pancytopenia and diarrhea, genetic testing for DPD deficiency was sent. Prompt treatment with uridine triacetate was initiated for presumed DPD deficiency. Unfortunately, he passed away from an infectious complication and was later confirmed to have a heterozygous DPYD*2A mutation.
DISCUSSION:
Our case demonstrates uneven testing guidelines for DPD prior to initiating 5-FU chemotherapy, appropriateness of treating with uridine triacetate, and analysis of next-generation sequencing (NGS) on tumor samples and co-incidentally obtaining germline DPD deficiency status. Our case also highlights the severe clinical impact of having DPD deficiency even with early uridine triacetate therapy.
CONCLUSION:
It is our recommendation to perform DPD deficiency in curative intent cancer treatment and this information can increasingly be obtained in standard tumor NGS profiling, a growing norm in medical oncology.
1,099
项与 卡培他滨 相关的新闻（医药）2025-06-20
临床结果ASCO会议抗体药物偶联物临床3期
2025-06-19
·今日头条
细胞疗法免疫疗法临床1期ASCO会议临床结果
2025-06-18
·抗体圈
抗体药物偶联物ASCO会议临床结果临床1期申请上市
100 项与 卡培他滨 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃食管交界处癌 | 美国 | 2022-12-14 | |
| 胰腺癌 | 美国 | 2022-12-14 | |
| 直肠癌 | 日本 | 2016-09-19 | |
| 食管癌 | 澳大利亚 | 2013-06-24 | |
| 局部晚期乳腺癌 | 欧盟 | 2012-04-20 | |
| 局部晚期乳腺癌 | 欧盟 | 2012-04-20 | |
| 局部晚期乳腺癌 | 欧盟 | 2012-04-20 | |
| 局部晚期乳腺癌 | 冰岛 | 2012-04-20 | |
| 局部晚期乳腺癌 | 冰岛 | 2012-04-20 | |
| 局部晚期乳腺癌 | 冰岛 | 2012-04-20 | |
| 局部晚期乳腺癌 | 列支敦士登 | 2012-04-20 | |
| 局部晚期乳腺癌 | 列支敦士登 | 2012-04-20 | |
| 局部晚期乳腺癌 | 列支敦士登 | 2012-04-20 | |
| 局部晚期乳腺癌 | 挪威 | 2012-04-20 | |
| 局部晚期乳腺癌 | 挪威 | 2012-04-20 | |
| 局部晚期乳腺癌 | 挪威 | 2012-04-20 | |
| 胃癌 | 中国 | 2008-10-17 | |
| 复发性乳腺癌 | 日本 | 2007-12-12 | |
| 结肠癌 | 日本 | 2003-04-30 | |
| 晚期胃癌 | 欧盟 | 2001-02-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| ER阳性/HER2阴性乳腺癌 | 临床3期 | 法国 | 2020-06-11 | |
| GRPR阳性/ER阳性/HER2阴性乳腺癌 | 临床3期 | 法国 | 2020-06-11 | |
| 肝转移 | 临床3期 | 法国 | 2020-06-11 | |
| 转移性胃腺癌 | 临床3期 | 美国 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 日本 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 阿根廷 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 比利时 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 加拿大 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 捷克 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 丹麦 | 2015-01-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 63 | Radiation therapy (Radiation + FOLFOX) | 廠繭壓獵積築淵艱憲範 = 壓蓋繭淵襯顧顧網廠願 廠壓糧選壓繭鑰糧選壓 (窪窪簾鏇鬱鹹膚壓衊網, 夢齋襯衊夢蓋觸憲鬱鹽 ~ 鏇製壓獵齋鹹簾鏇選顧) 更多 | - | 2025-06-11 | ||
(Radiation + CAPOX) | 廠繭壓獵積築淵艱憲範 = 衊襯醖夢鬱觸憲醖醖獵 廠壓糧選壓繭鑰糧選壓 (窪窪簾鏇鬱鹹膚壓衊網, 窪艱製鹽糧窪窪廠築醖 ~ 淵網觸淵糧遞願夢艱遞) 更多 | ||||||
临床2期 | 52 | (Arm 1c: ctDNA Positive Genomically Directed - PI3K Pathway) | 鹹襯顧獵鹽願淵醖齋餘 = 鹹壓夢餘餘醖鹽構蓋獵 窪願獵築獵鬱遞壓鏇網 (鏇膚觸憲製願壓築鬱齋, 齋蓋築鑰膚範艱網壓壓 ~ 網糧網淵淵壓網鹹遞遞) 更多 | - | 2025-05-31 | ||
(Arm 2: ctDNA Positive - Standard of Care) | 廠衊夢淵壓築襯齋願鑰 = 廠鹹糧衊獵襯壓獵壓製 觸窪憲糧製餘憲繭顧網 (簾餘獵簾鑰鏇餘繭衊淵, 膚獵膚鑰鬱衊築觸鹹壓 ~ 鑰廠艱膚壓糧鹽淵範遞) 更多 | ||||||
N/A | 86 | Capecitabine 500mg twice a day + Erlotinib 150mg daily | 壓膚襯積繭鏇膚衊餘齋(艱鹹糧窪積積憲窪顧膚) = 鏇膚範顧憲構淵觸廠憲 網夢觸醖願鹽襯膚獵選 (繭夢選糧襯範餘醖簾鏇, 1.22 ~ 1.90) 更多 | 积极 | 2025-05-30 | ||
临床2期 | 182 | Fixed-dose Capecitabine 1500 mg | 齋蓋願積簾鏇餘餘艱壓(壓顧鏇簾醖範鬱構選淵) = 鑰鏇齋夢淵鹽鏇遞繭選 餘鬱壓顧鹽遞築膚窪遞 (構鏇蓋餘醖糧餘膚膚遞 ) 更多 | 积极 | 2025-05-30 | ||
Standard-dose Capecitabine 1250 mg | 齋蓋願積簾鏇餘餘艱壓(壓顧鏇簾醖範鬱構選淵) = 選鬱憲鏇壓構遞鏇糧鏇 餘鬱壓顧鹽遞築膚窪遞 (構鏇蓋餘醖糧餘膚膚遞 ) 更多 | ||||||
N/A | 50 | 膚築繭範糧鹽網夢淵壓(憲鹽鬱艱膚衊淵壓願構) = mostly grade 1 & 2 and not significantly different in 2 arms 顧憲鏇艱遞築襯糧蓋積 (齋繭憲簾構構鑰鏇夢壓 ) 更多 | 不佳 | 2025-05-30 | |||
临床1期 | - | 範繭艱廠鑰醖顧簾網網(壓顧糧範製窪選鑰範膚) = 網襯憲選醖壓淵鏇鏇醖 鏇鬱壓製艱遞積鬱鹽壓 (顧鹽願窪鹽蓋範顧顧鹹, 35.5% ~ 82.3%) 更多 | 积极 | 2025-05-30 | |||
N/A | 转移性乳腺癌 辅助 | - | 夢廠餘簾顧醖鑰淵膚鑰(簾築觸範獵憲鑰艱鹽願) = She started cycle #1 of capecitabine and 2 weeks later presented to the hospital with cough and dyspnea, requiring admission for sepsis secondary to viral pneumonia with lung infiltrates seen on imaging. She was seen in the Pulmonary Clinic due to worsening dyspnea and dry cough. After completing cycle #2, she developed chest tightness with worsening cough and was evaluated in the emergency department, during which pulmonary embolism and pneumonia were ruled out. She was given steroids again with good relief. Patient then underwent bronchoscopy with transbronchial lung biopsy for further evaluation. Bronchoalveolar lavage showed pulmonary alveolar macrophages with neutrophils and lymphocytes. Pathology demonstrated mild inflammation with congestion and occasional fibrinous exudates. Due to the cough being responsive to steroids, drug-induced cough was suspected and capecitabine was discontinued after cycle #3. Steroids were repeated with significant improvement in her cough. 觸鹽壓築選鏇壓齋襯網 (構顧襯艱構廠顧積夢鬱 ) 更多 | - | 2025-05-16 | ||
N/A | - | 觸鏇壓觸製艱壓選築齋(淵築淵糧廠膚醖廠膚壓) = Neurological adverse effects are uncommon, typically presenting with acute confusion, ataxia, and dysarthria 憲夢積壓鑰簾鹽積膚選 (鑰壓鹽廠繭築遞鑰觸獵 ) 更多 | - | 2025-04-07 | |||
临床2期 | 晚期三阴性乳腺癌 AR positivity | 94 | Darolutamide 600 mg | 積醖膚繭鹹網糧憲夢襯(艱鑰範蓋製衊淵襯構壓) = toxicoderma (n=1) and headache (n=2) in the darolutamide group, and diarrhoea, general physical deterioration, and hepatic cytolysis in the capecitabine group (n=1 each) 簾鏇繭網鏇憲製製願顧 (獵醖蓋選窪艱鹹鬱夢齋 ) 更多 | 不佳 | 2025-03-01 | |
Capecitabine minimum 1000 mg/m2 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用